Celon Pharma Capital Markets Day – 21.04.2021

Capital Markets Day to be held on Wednesday, April 21, 2021 at 10:00 AM ET / 16:00 Warsaw Time Zone. Join Corporate and KOL’s session. Prof. Eduard Vieta Chair at the University of Barcelona and Head of the Department of Psychiatry and Psychology at the Hospital Clinic and Prof. Jair C. Soares, MD, PhD –Read more »

Celon Pharma in the Stock Exchange Company of the Year ranking

Celon Pharma took 2nd place in the Development prospects category in the 22nd edition of the Stock Exchange Company of the Year 2020. The GSR report was prepared on the basis of an assessment of companies in the course of a special online survey in which companies & nbsp; to be assessed in accordance withRead more »

Current report No. 7/2021 – The recommendation of the National Centre for Research and Development to co-fund a project for an inhaled drug candidate for the treatment of inflammatory and fibrotic lung diseases, including COVID-19 complications

February 10, 2021 Date: February 10, 2021, time: 5:42 PM Legal basis: Article 17 section 1 of the Market Abuse Regulation (MAR) – confidential information. Content of the report: Management Board of Celon Pharma S.A. (the “Company”) wishes to announce that on 10 February 2021 it received information that the Company’s application for co-funding ofRead more »

Celon Pharma Announces Successful Completion of Phase 1A Trial of CPL’116, JAK-ROCK Inhibitor.

Celon Pharma S.A. today announced the successful completion of its Phase 1A trial of its JAK/ROCK kinases dual inhibitor, CPL’116. CPL’116 was administered orally in single ascending doses in healthy volunteers in order to assess safety and pharmacokinetic parameters (PK). No adverse events associated with administration of the investigational drug were observed, and the trial metRead more »

Current report No. 6/2021 – Completion of a phase IA clinical trial of a drug based on an innovative JAK/ROCK inhibitor – CPL 409116

February 9, 2021 Date: February 9, 2021, time: 8:56 AM Legal basis: Article 17 section 1 of the Market Abuse Regulation (MAR) – confidential information. In relation to the current report No. 39/2020 of 12 November 2020 on receiving approval for a Phase I clinical trial of a drug based on an innovative JAK/ROCK inhibitorRead more »

Current report No. 3/2021 – Obtaining a patent for GPR40 receptor agonists and their use in T2D treatment in the US

Subject: Obtaining a patent for GPR40 receptor agonists and their use in T2D treatment in the US Legal basis: Article 17 section 1 of the Market Abuse Regulation (MAR) – confidential information, time: 4:42 PM Content of the report: Management Board of Celon Pharma S.A. (the “Company”) wishes to announce that on January 18, 2021,Read more »

Current report No. 2/2021 – The National Centre for Research and Development recommended co-funding of the project dedicated to the development of a drug based on GPR40 receptor agonists in the treatment of neuropathic pain

Subject: The National Centre for Research and Development recommended co-funding of the project dedicated to the development of a drug based on GPR40 receptor agonists in the treatment of neuropathic pain Legal basis: Article 17 section 1 of the Market Abuse Regulation (MAR) – confidential information, time: 4:27 PM Content of the report: Management BoardRead more »

Celon Pharma at Top Picks by Trigon Investor Conference

On January 21, 2021, representatives of the Company’s Management Board will take part in the Top Picks by Trigon conference. Celon Pharma was among 21 companies recommended by Trigon DM in 2021.

Celon Pharma Announces Positive Falkieri Phase II Results in Treatment-Resistant Bipolar Depression

Jan 8, 2020—Celon Pharma ($CLN.PL) today announced positive top-line results from a Phase II study of Falkieri (proprietary esketamine dry powder inhalation) in acute phase of treatment-resistant bipolar depression. View the webcast from TC See the presentation from the Meeting.  In the trial, Falkieri met the primary endpoint with statistically significant reductions in MADRS total scoreRead more »